Navigation Links
Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program
Date:9/3/2008

ansplants in the United States are due to HCV.

Currently, there is no vaccine against Hepatitis C available, and the infection can only be treated with a combination of Interferon and Ribavirin -- a long-term therapy with limited efficacy and substantial side effects. It also gives rise to high treatment costs for patients. In 2002, worldwide sales of HCV drugs totalled around EUR 2.8bn, and demand has since grown significantly. The market has been seen to expand to about EUR 3.5bn by 2006.

About Intercell AG

Intercell AG is a growing biotechnology company that designs and develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. The Company's technology platforms include an antigen-discovery system, two proprietary adjuvants and a novel patch-based delivery system. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, Sanofi Pasteur, Kirin and the Statens Serum Institut.

The Company's lead product is a vaccine against Japanese Encephalitis. That vaccine successfully concluded pivotal Phase III clinical trials in 2006, and Intercell is seeking marketing approval in the United States, Europe, Australia and Canada. Approval in those markets is anticipated during the second half of 2008.

The Company's development pipeline includes Phase II vaccine programs for Pseudomonas (in-house development) and S. aureus, which is being developed with Merck & Co. Inc. The Company's novel Travelers' Diarrhea vaccine patch will enter Phase III testing in 2009. Intercell is also in clinical trials of a vaccine enhancement patch with injected pandemic influenza vaccines (one shot plus patch). In addition, five other products focused on infectious diseases are in preclinical development.

Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more info
'/>"/>

SOURCE Intercell AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months
2. FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
3. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
4. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
5. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
6. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
7. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
8. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
9. Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinsons Disease
10. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
11. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Growth of the U.S. nonprescription market is primarily ... users to the OTC market. Due to an increasingly ... switch activity over the next five years with several ... brands entering the market into existing categories. ... (even those with low to moderate likelihood), the market ...
(Date:7/30/2015)... N.J. , July 30, 2015  Medimetriks ... completed the second Phase III clinical study for ... for impetigo.  Medimetriks owns the exclusive U.S. rights ... global trial, conducted at 44 centers with an ... pediatric patients aged 2 months and older with ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
Breaking Medicine Technology:Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
(Date:7/31/2015)... ... July 31, 2015 , ... ... RenovoCath,™ a novel catheter that was developed for targeted delivery of fluids to ... now being treated at Florida Hospital Tampa with the device that provides direct, ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Awarded to only ... is proud to announce that they are the latest recipients of the Center ... status as one of the worldwide leaders in the science of hair transplant. , ...
(Date:7/31/2015)... ... July 31, 2015 , ... Healthpointe , a multidisciplinary ... website at Healthpointe.net. The new website will feature a sleek and streamlined design ... to provide smoother interactions between patients and the Healthpointe clinics and ensures that ...
(Date:7/31/2015)... ... July 31, 2015 , ... The ... Karmanos Center for Natural Birth . The Karmanos Center for Natural Birth ... childbirth experience. With nurses and caregivers that are trained in holistic birth approaches, ...
(Date:7/31/2015)... MI (PRWEB) , ... July 31, 2015 , ... ... Essential Oils are 100% organic, natural, therapeutic-grade oils from ingredients sourced all over ... Eilers, explains that “With considerable effort, we have developed the highest-quality oils in ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Healthpointe Announces Newly Redesigned Website 2Health News:Living Pure Essential Oils takes Therepeutic Essential Oil Market by Storm 2
... , , , ... Pharmaceuticals, Inc. (Nasdaq: AMLN ) today reported financial results for ... $209.4 million for the quarter ended June 30, 2009, which includes net ... million associated with the Company,s sales force reduction in the second quarter, ...
... Wednesday, August 5, 2009, ... 9:00 a.m. EDT, ... 1-800-731-5774, ... to participate in a briefing on Wednesday, August 5, with David B. Holtz, Interim President Chief Executive ...
... , MEQUON, Wis., July 21 Wonderbox ... its clients to benefit from continued advances in technology and ... Management Module designed for managed care benefit administration and case ... tools for scheduling, managing, and monitoring day-to-day care tasks and ...
... American men could be putting their health at risk ... results might threaten their masculinity. Because they prove their ... advice including HIV/AIDS testing goes against their notion of ... Department of Sociology at Yale University in the US, ...
... Mich., July 21 The Michigan Chamber of Commerce ... health care reform and urged Michigan,s Congressional Delegation to demand ... , , "Like the U.S. ... and the President to reform the health care system for ...
... , , OWINGS MILLS, Md., ... leading portion-controlled weight-loss program, today announced the launch of Honey Mustard ... and Parmesan Cheese Puffs. The new pretzel sticks and cheese puffs ... & 1 Plan, while also maintaining the nutritional value of Medifast ...
Cached Medicine News:Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 2Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 3Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 4Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 5Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 6Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 7Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 8Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 9Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 10Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 11Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 12Health News:Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 Second Quarter Results 2Health News:Wonderbox Technologies(R) Releases Version 4.5 of the Enterprise System 2Health News:'Go to the doctor? Only if I'm really sick ...' 2Health News:Michigan Chamber of Commerce Raises Concerns With Flawed Federal Health Care Reform Proposal, Rushed Timeline 2Health News:Medifast Adds Pretzel and Puffs to Meal Replacement Line 2Health News:Medifast Adds Pretzel and Puffs to Meal Replacement Line 3